New Release

Prevention and Early Detection of Human Tumours

Second edition

About the book:

In 2014 World Health Organization (WHO) reported that during the next 25 years the number of cancer cases would increase by about 70% worldwide. In order to deal with this dramatic increase, WHO suggested to focus on prevention, early detection and early treatment of human tumour by health screening. We have worked on this topic for more than 30 years resulting in detection of precancerous lesions to enable early intervention in clinical oncology, preventing cancer progression and reducing mortality. A new model has been developed – Prevention, Early Detection and Early Treatment Tumourigenesis – based on oxidative stress (8-oxo-dG) and a reliable tumour proliferation biomarker (human thymidine kinase 1 (HTK1) in serum (STK1). STK1 assay by IgY polyclonal antibody against HTK1 is able to discover invisible malignant tumours before the appearance of tumour loci in modern imaging. It is not only in the clinical evaluation of prognosis, recurrence risk, and survival in cancer patients but also for early tumour screening especially, showing that people with elevated STK1 levels in their blood have a 3-5 times higher risk to develop malignancy within 11 years.

About the Authors

Prof. Sven Skog

Sven Skog (PhD, Professor, Doctoral tutor) graduated as a molecular cell biologist from Stockholm University in 1975. He continued his research on cell cycle regulation in relation to cancer therapies (radiation, chemotherapy, hyperthermia, endocrine treatment) at Karolinska Institute. Dr. Skog earned his Dr. Med. Sci. (PhD) degree in 1985 on cell cycle regulation in relation to cancer therapies, under Prof. Bernhard Tribukait, Department of Medical Radiobiology, Karolinska Institute. He was accepted as Associated Prof. in 1995 and earned his Prof. degree in 2005, from Karolinska Institute. He was awarded by the Swedish Oncology Society several times for his research work. Dr. Skog has been working as a full-time researcher since 1978, teaching graduated students and supervising PhD students, of which 18 have graduated. He has published more than 180 papers and conference abstracts in peer-reviewed scientific journals. Dr. Skog was chief of the Oncology Research Laboratory at Huddinge University Hospital from 2000-2005. Dr, Skog has been working as a scientific adviser for the Sino-Swed TongKang (SSTK) Bio-Tech. Inc., China (www.sstkbiotech.com) and now he is an honorary director at the Shenzhen Ellen-Sven Precision Medicine Institute, China. Because of his scientific work in China, he was accepted as a Foreign Expert in China and performed extensive oncology clinic research works on the TK1 topic in China, resulting in more than 250 research publications, in cooperation with Chinese researchers/oncology doctors. In cooperation with the company SSTK Inc., they established TK1 as a reliable biomarker for risk assessment of the development of human tumours and early detection of tumours in health screening based on more than 160,000 tests, published in international scientific journals.

About the Authors

Ellen He

Ellen He (PhD, Associate Professor, Doctoral tutor) graduated in biology/biochemistry from Wuhan University, China, in 1963. In 1986, Dr. He moved to the Department of Medical Radiobiology, Karolinska Institute, Stockholm, Sweden, as a post-doc researcher. In 1990, she graduated as Dr. Med. Sci. (PhD) under Prof. Bernhard Tribukait, of Karolinska Institute, Sweden, on a study of Human Thymidine Kinase 1 (HTK1) in clinical application. In 2004 Dr. He was accepted as Associated Prof at Karolinska Institute. Dr. He has been working as a full-time researcher and doctoral tutor at Karolinska Institute and the Swedish University of Agricultural Sciences from 1990–2012. Since 2002, Dr. He guided the Sino-Swed TongKang Bio-Tech. Inc. (www.sstkbiotech.com) to develop TK1 in clinical applications based on IgY-antibodies against human-TK1 for use in human blood serum, which is now a commercial TK1 kit, which set up by theSino-Swed TongKang Bio-Tech. Inc., China. Dr. He has been working as a chief scientist at the Shenzhen Ellen-Sven Precision Medicine Institute, China, and accepted as Foreign Expert in China. Dr. He has cooperated with research groups in Sweden, England, and China for more than 30 years, on the topics of TK1. She is also the co-author of several scientific textbooks, written in both English and Chinese, and participated as a speaker in a number of conferences and workshops regarding basic knowledge of cell cycle regulation, and specific clinical use of TK1. Dr. He has published more than 90 papers in peer-reviewed scientific journals and more than 25 conference abstracts. There are about 100 publications on TK1 in clinical use based on Dr. He’s pioneer work on the use of TK1 in oncology and health screening of human cancer.

About the Authors

Siamak Haghdoost

Siamak Haghdoost (PhD, Professor, Doctoral tutor) has a background in being a Radiotherapy Technologist at The Department of Radiation Oncology, Karolinska Institute, Stockholm, Sweden, followed by studies in cell biology and radiation biology at Stockholm University, Sweden. He graduated in 2006 with a PhD in Genetic Toxicology, under Prof. Mats Harms-Ringdahl, on a subject related to oxidative stress and individual radiosensitivity. Dr. Haghdoost has been working since 2007 as a full-time researcher at the Department of Molecular Bioscience, The Wenner-Green Institute, Stockholm University. He obtained his associate professorship at Stockholm University in 2013 and was a research group leader in 2015. In 2018, he became Professor at the University of Caen, France, Medical Radiation Oncology. Dr. Haghdoost is a dedicated teacher at the bachelor and master levels as well as for PhD students. Since 2011, Dr. Haghdoost has established extensive scientific collaborations with research groups at Karolinska Institute, Hirosaki University, Japan, Sao Paulo University, Brazil and researchers in China, France and Iran. He has a position as a Foreign Expert in China since he works as a scientific adviser for a biotech company in China (Sino-Swed TongKang Bio-Tech. Inc., SSTK Inc., China, www.sstkbiotech.com). Dr. Haghdoost has been awarded by the Polish Radiation Research Society for his scientific work. He is the chairman of the Swedish Radiation Society, a council member of the European Radiation Research Society, as well as been a member of a number of scientific conferences and workshops on radiation- and stress-related subjects during the last 10 years. Dr. Haghdoost has published more than 50 papers in peer-reviewed scientific journals.